shattucklabs.com (STTK) - Long-Term Debt to Capital Coefficient

Shattuck Labs, Inc. (STTK) develops advanced proteins for immune activation in cancer therapy. This long-term debt-to-equity chart illustrates financial stability, where the value 0.01 represents the current metric. High testing costs create a capital deficit, yet a strong team of immunologists and the protection of core competencies provide the company with long-term growth potential.

Shattuck Labs, Inc. (STTK) utilizes a production and testing outsourcing model to minimize capital expenditures. This indicator is calculated as the ratio of loans with a maturity of more than one year to equity. It allows for an assessment of the issuer's long-term leverage and financial stability. The metric reveals hidden over-indebtedness risks during external shocks. By analyzing the dynamics of the long-term debt-to-equity ratio, an investor can discern the company's actual degree of dependence on borrowed funds.